News & Updates
Filter by Specialty:
Rituximab-temozolomide-radiation combo shows promise in recurrent primary CNS lymphoma
Use of rituximab, temozolomide, and radiation appears safe and effective as salvage therapy for patients with recurrent or refractory primary central nervous system (CNS) lymphoma, according to a study in the Philippines, the results of which were presented at the recent AAN 2023.
Rituximab-temozolomide-radiation combo shows promise in recurrent primary CNS lymphoma
15 May 2023
Toripalimab plus bevacizumab, SoC demonstrates promising efficacy for cervical cancer
Preliminary results of a single-arm, open-label, phase II trial demonstrated the efficacy of a combination regimen comprising toripalimab, bevacizumab, and platinum-based chemotherapy for women with refractory, recurrent, or metastatic cervical cancer.
Toripalimab plus bevacizumab, SoC demonstrates promising efficacy for cervical cancer
15 May 2023
Temporary ET break for pregnancy safe in the short term for breast cancer survivors
Temporary interruption of adjuvant endocrine therapy (ET) to allow for pregnancy has demonstrated short-term safety, with no increase in risk of breast cancer events, including distant recurrence, in hormone receptor–positive breast cancer survivors who have completed 18–30 months of adjuvant ET.